5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
NEUTRAL | BUY | BUY | BUY | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 0.60▼ | 0.60▼ | 0.60▼ | 0.58▲ | 0.60▼ |
MA10 | 0.60▼ | 0.60▼ | 0.59▲ | 0.58▲ | 0.57▲ |
MA20 | 0.60▼ | 0.59▲ | 0.59▲ | 0.61▼ | 0.55▲ |
MA50 | 0.60▲ | 0.58▲ | 0.59▲ | 0.57▲ | 0.68▼ |
MA100 | 0.59▲ | 0.59▲ | 0.61▼ | 0.55▲ | 0.78▼ |
MA200 | 0.58▲ | 0.61▼ | 0.61▼ | 0.64▼ | 3.95▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.000▲ | 0.000▲ | 0.003▲ | -0.007▼ | 0.019▲ |
RSI | 49.550▼ | 55.698▲ | 55.524▲ | 51.246▲ | 49.665▼ |
STOCH | 80.878▲ | 58.510 | 85.350▲ | 26.283 | 52.321 |
WILL %R | -80.147▼ | -33.232 | -22.110▲ | -68.785 | -53.654 |
CCI | -24.289 | 12.690 | 60.152 | -25.229 | 37.336 |
Monday, July 07, 2025 05:00 PM
Veru's focus on lean body mass differentiates its candidate from others in the weight-loss category, although, other companies including Eli Lilly through its 2023 acquisition of Versanis, ...
|
Tuesday, June 24, 2025 05:31 AM
Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After ...
|
Wednesday, June 11, 2025 05:43 AM
Veru Inc. will engage with investors at the virtual BTIG Obesity Health Forum on June 18, 2025.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
11/07/25 | 0.599 | 0.61 | 0.5808 | 0.6005 | 1,566,500 |
10/07/25 | 0.5515 | 0.5948 | 0.55 | 0.5832 | 1,272,074 |
09/07/25 | 0.60 | 0.60 | 0.544 | 0.5535 | 2,391,418 |
08/07/25 | 0.58 | 0.5898 | 0.5615 | 0.58 | 1,416,779 |
07/07/25 | 0.61 | 0.62 | 0.58 | 0.58 | 978,500 |
03/07/25 | 0.60 | 0.6179 | 0.5901 | 0.6066 | 897,985 |
02/07/25 | 0.587 | 0.604 | 0.5702 | 0.5836 | 1,544,340 |
01/07/25 | 0.59 | 0.60 | 0.5801 | 0.59 | 1,163,324 |
30/06/25 | 0.5815 | 0.6096 | 0.58 | 0.5818 | 1,474,686 |
27/06/25 | 0.6501 | 0.6501 | 0.5815 | 0.5815 | 18,778,440 |
|
|
||||
|
|
||||
|
|